-
Posted by
Two Blokes Jun 22 -
Filed in
Stock
-
5 views
Q1 results exceeded expectations, driven by strong Biopharmaceutical and Diagnostic Solutions growth and margin expansion from scaling new facilities. 2025 guidance was reaffirmed despite FX headwinds and Engineering division weakness. High-value products continue to support a robust profit outlook and with a positive sales guidance, we confirm our buy rating.
